A Double-blind Placebo Controlled Study of Desipramine in the Treatment of ADD: II. Serum Drug Levels and Cardiovascular Findings

Abstract
No abstract available
Funding Information
  • Merrell-Dow Pharmaceutical Company and the Charlupski Foundation (MH-31154, MH-36224. and MH-47370)